The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Biotech Co. Unveils Scalable AI Voice Biomarker Platform
Source: Streetwise Reports (05/13/2026)

MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) CEO says proprietary AI voice analytics could transform impairment screening across zero-tolerance industries.

D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Source: Streetwise Reports (05/11/2026)

BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.

Biotech Co. Advances AI Detection Breakthrough for Intoxication Safety
Source: Streetwise Reports (05/11/2026)

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) enhances AI speech analysis tech with cross-language capability, paving the way for major accident-prevention potential.